ResearchMoz

Oncology Market Research Reports & Industry Analysis

Oncology Market Research Reports & Industry Analysis Oncology

Browse reports in Oncology

Displaying 1 to 30 (of 353 records)
Pages: « Last  1 2 3 4 5 6 7 8 9 10   Next »
PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players
May 2013   |   By - GlobalData
PharmaPoint: Chronic Myeloid Leukemia (CML) Current and Future Players Summary GlobalData has released its pharma report, PharmaPoint: Chronic Myeloid Leukemia (CML) Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing CML Market. The report identifies and analyses the key...
$2995
Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
May 2013   |   By - GlobalData
Gleevec (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Gleevec (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The...
$3495
Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
May 2013   |   By - GlobalData
Sprycel (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Sprycel (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion...
$3495
Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
May 2013   |   By - GlobalData
Tasigna (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Tasigna (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The...
$3495
Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
May 2013   |   By - GlobalData
Bosulif (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Bosulif (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The...
$3495
Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
May 2013   |   By - GlobalData
Iclusig (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Iclusig (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The...
$3495
Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022
May 2013   |   By - GlobalData
Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The...
$3495
PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022
Apr 2013   |   By - GlobalData
PharmaPoint: Chronic Myeloid Leukemia (CML) United States Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) United States Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence...
$4995
PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022
Apr 2013   |   By - GlobalData
PharmaPoint: Chronic Myeloid Leukemia (CML) France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) France Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the...
$4995
PharmaPoint: Chronic Myeloid Leukemia (CML) - Germany Drug Forecast and Market Analysis to 2022
Apr 2013   |   By - GlobalData
PharmaPoint: Chronic Myeloid Leukemia (CML) Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) Germany Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the...
$4995
PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022
Apr 2013   |   By - GlobalData
PharmaPoint: Chronic Myeloid Leukemia (CML) Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) Italy Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL...
$4995
PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022
Apr 2013   |   By - GlobalData
PharmaPoint: Chronic Myeloid Leukemia (CML) Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) Spain Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL...
$4995
PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022
Apr 2013   |   By - GlobalData
PharmaPoint: Chronic Myeloid Leukemia (CML) United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) United Kingdom Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by...
$4995
PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022
Apr 2013   |   By - GlobalData
PharmaPoint: Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL...
$4995
Breast Cancer Pipeline Review, H1 2013
Apr 2013   |   By - Global Markets Direct
Breast Cancer Pipeline Review, H1 2013 Summary Global Markets Directs, 'Breast Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews...
$2500
Ovarian Cancer Pipeline Review, H1 2013
Apr 2013   |   By - Global Markets Direct
Ovarian Cancer Pipeline Review, H1 2013 Summary Global Markets Directs, 'Ovarian Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also...
$2500
Lung Cancer Pipeline Review, H1 2013
Apr 2013   |   By - Global Markets Direct
Lung Cancer Pipeline Review, H1 2013 Summary Global Markets Directs, 'Lung Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players...
$2000
Squamous Cell Carcinoma Pipeline Review, H1 2013
Apr 2013   |   By - Global Markets Direct
Squamous Cell Carcinoma Pipeline Review, H1 2013 Summary Global Markets Directs, 'Squamous Cell Carcinoma Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued...
$2000
Glioma Pipeline Review, H1 2013
Apr 2013   |   By - Global Markets Direct
Glioma Pipeline Review, H1 2013 Summary Global Markets Directs, 'Glioma Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved...
$2000
Kidney Cancer (Renal Cell Cancer) Pipeline Review, H1 2013
Apr 2013   |   By - Global Markets Direct
Kidney Cancer (Renal Cell Cancer) Pipeline Review, H1 2013 Summary Global Markets Directs, 'Kidney Cancer (Renal Cell Cancer) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer (Renal Cell Cancer), complete with latest updates, and special...
$2000
Sarcomas Pipeline Review, H1 2013
Apr 2013   |   By - Global Markets Direct
Sarcomas Pipeline Review, H1 2013 Summary Global Markets Directs, 'Sarcomas Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Sarcomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players...
$2000
Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, H1 2013
Apr 2013   |   By - Global Markets Direct
Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, H1 2013 Summary Global Markets Directs, 'Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) , complete with latest updates, and...
$2000
T-Cell Lymphomas Pipeline Review, H1 2013
Apr 2013   |   By - Global Markets Direct
T-Cell Lymphomas Pipeline Review, H1 2013 Summary Global Markets Directs, 'T-Cell Lymphomas Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for T-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also...
$2000
Non -Hodgkin Lymphoma - Pipeline Review, H1 2013
Mar 2013   |   By - Global Markets Direct
Non -Hodgkin Lymphoma Pipeline Review, H1 2013 Summary Global Markets Directs, 'Non -Hodgkin Lymphoma Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Non -Hodgkin Lymphoma, complete with latest updates, and special features on late -stage and discontinued...
$2000
Bone Cancer - Pipeline Review, H1 2013
Mar 2013   |   By - Global Markets Direct
Bone Cancer Pipeline Review, H1 2013 Summary Global Markets Directs, 'Bone Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bone Cancer, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key...
$2000
Colon Carcinoma - Pipeline Review, H1 2013
Mar 2013   |   By - Global Markets Direct
Colon Carcinoma Pipeline Review, H1 2013 Summary Global Markets Directs, 'Colon Carcinoma Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Colon Carcinoma, complete with latest updates, and special features on late -stage and discontinued projects. It also...
$2000
Type 2 Diabetes Pipeline Review, H1 2013
Mar 2013   |   By - Global Markets Direct
Type 2 Diabetes Pipeline Review, H1 2013 Summary Global Markets Directs, 'Type 2 Diabetes Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Type 2 Diabetes, complete with latest updates, and special features on late-stage and discontinued projects. It also...
$2500
Multiple Sclerosis Pipeline Review, H1 2013
Mar 2013   |   By - Global Markets Direct
Multiple Sclerosis Pipeline Review, H1 2013 Summary Global Markets Directs, 'Multiple Sclerosis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Multiple Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It...
$2000
Hypertension Pipeline Review, H1 2013
Mar 2013   |   By - Global Markets Direct
Hypertension Pipeline Review, H1 2013 Summary Global Markets Directs, 'Hypertension Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key...
$2000
Kidney Disease Pipeline Review, H1 2013
Mar 2013   |   By - Global Markets Direct
Kidney Disease Pipeline Review, H1 2013 Summary Global Markets Directs, 'Kidney Disease Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Kidney Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also...
$2000
 
Displaying 1 to 30 (of 353 records)
Pages: « Last  1 2 3 4 5 6 7 8 9 10   Next »